Structural consequences of aglycosylated IgG Fc variants evolved for FcγRI binding

Molecular Immunology

Volumn 67, Issue 2, 2015, Pages 350-356

  Ju, Man Seok ^a   Na, Jung Hyun ^a,b   Yu, Yeon Gyu ^a   Kim, Jae Yeol ^c   Jeong, Cherlhyun ^d   Jung, Sang Taek ^a  

^a Kookmin University   (South Korea)

^b Korea Research Institute of Ships and Ocean Engineering   (South Korea)

^c Pohang University of Science and Technology (POSTECH)   (South Korea)

^d Korea Institute of Science and Technology   (South Korea)

Author keywords

Aglycosylated antibody; Alternative laser excitation; Antibody engineering; Effector function; F rster resonance energy transfer; Single molecule analysis

Indexed keywords

IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; TRICHLOROFLUOROMETHANE; FC RECEPTOR; GLYCOSYLATED IGG; IMMUNOGLOBULIN G; MUTANT PROTEIN; PROTEIN BINDING;

ANIMAL CELL; ANTIBODY ENGINEERING; ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DEGLYCOSYLATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENETIC VARIABILITY; HUMAN; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; RECEPTOR BINDING; WILD TYPE; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN CONFORMATION; PROTEIN ENGINEERING; PROTEIN STABILITY; X RAY CRYSTALLOGRAPHY;

ANIMALS; CRYSTALLOGRAPHY, X-RAY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MICE; MODELS, MOLECULAR; MUTANT PROTEINS; POINT MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN ENGINEERING; PROTEIN STABILITY; RECEPTORS, IGG;

EID: 84940959004     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2015.06.020     Document Type: Article

References (41)

1. Alsenaidy M.A., Kim J.H., Majumdar R., Weis D.D., Joshi S.B., Tolbert T.J., Middaugh C.R., Volkin D.B. High-throughput biophysical analysis and data visualization of conformational stability of an IgG1 monoclonal antibody after deglycosylation. J. Pharm. Sci. 2013, 102:3942-3956.
2. Borrok M.J., Jung S.T., Kang T.H., Monzingo A.F., Georgiou G. Revisiting the role of glycosylation in the structure of human IgG Fc. ACS Chem. Biol. 2012, 7:1596-1602.
3. Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-ANG. resolution. Biochemistry 1981, 20:2361-2370.
4. Deniz A.A., Laurence T.A., Beligere G.S., Dahan M., Martin A.B., Chemla D.S., Dawson P.E., Schultz P.G., Weiss S. Single-molecule protein folding: diffusion fluorescence resonance energy transfer studies of the denaturation of chymotrypsin inhibitor 2. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:5179-5184.
5. Elvin J.G., Couston R.G., van der Walle C.F. Therapeutic antibodies: market considerations, disease targets and bioprocessing. Int. J. Pharm. 2013, 440:83-98.
6. Feige M.J., Nath S., Catharino S.R., Weinfurtner D., Steinbacher S., Buchner J. Structure of the murine unglycosylated IgG1 Fc fragment. J. Mol. Biol. 2009, 391:599-608.
7. Ha S., Ou Y., Vlasak J., Li Y., Wang S., Vo K., Du Y., Mach A., Fang Y., Zhang N. Isolation and characterization of IgG1 with asymmetrical Fc glycosylation. Glycobiology 2011, 21:1087-1096.
8. Ha T., Ting A.Y., Liang J., Caldwell W.B., Deniz A.A., Chemla D.S., Schultz P.G., Weiss S. Single-molecule fluorescence spectroscopy of enzyme conformational dynamics and cleavage mechanism. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:893-898.
9. Henzler-Wildman K., Kern D. Dynamic personalities of proteins. Nature 2007, 450:964-972.
10. Hristodorov D., Fischer R., Joerissen H., Muller-Tiemann B., Apeler H., Linden L. Generation and comparative characterization of glycosylated and aglycosylated human IgG1 antibodies. Mol. Biotechnol. 2013, 53:326-335.
11. Jefferis R. Glycosylation of recombinant antibody therapeutics. Biotechnol. Prog. 2005, 21:11-16.
12. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discov. 2009, 8:226-234.
13. Jefferis R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends. Pharmacol. Sci. 2009, 30:356-362.
14. Jeong C., Cho W.K., Song K.M., Cook C., Yoon T.Y., Ban C., Fishel R., Lee J.B. MutS switches between two fundamentally distinct clamps during mismatch repair. Nat. Struct. Mol. Biol. 2011, 18:379-385.
15. Ju M.S., Jung S.T. Aglycosylated full-length IgG antibodies: steps toward next-generation immunotherapeutics. Curr. Opin. Biotechnol. 2014, 30C:128-139.
16. Jung S.T., Reddy S.T., Kang T.H., Borrok M.J., Sandlie I., Tucker P.W., Georgiou G. Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:604-609.
17. Jung S.T., Kang T.H., Kelton W., Georgiou G. Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy. Curr. Opin. Biotechnol. 2011, 22:858-867.
18. Jung S.T., Kelton W., Kang T.H., Ng D.T., Andersen J.T., Sandlie I., Sarkar C.A., Georgiou G. Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcgammaRIIa affinity and selectivity. ACS Chem. Biol. 2013, 8:368-375.
19. Kawarasaki Y., Griswold K.E., Stevenson J.D., Selzer T., Benkovic S.J., Iverson B.L., Georgiou G. Enhanced crossover SCRATCHY: construction and high-throughput screening of a combinatorial library containing multiple non-homologous crossovers. Nucleic Acids Res. 2003, 31:e126.
20. Kelliher M.T., Jacks R.D., Piraino M.S., Southern C.A. The effect of sugar removal on the structure of the Fc region of an IgG antibody as observed with single molecule Forster resonance energy transfer. Mol. Immunol. 2014, 60:103-108.
21. Kim C., Kim J.Y., Kim S.H., Lee B.I., Lee N.K. Direct characterization of protein oligomers and their quaternary structures by single-molecule FRET. Chem. Commun. (Camb.) 2012, 48:1138-1140.
22. Kim J.Y., Choi B.K., Choi M.G., Kim S.A., Lai Y., Shin Y.K., Lee N.K. Solution single-vesicle assay reveals PIP2-mediated sequential actions of synaptotagmin-1 on SNAREs. EMBO J. 2012, 31:2144-2155.
23. Krapp S., Mimura Y., Jefferis R., Huber R., Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J. Mol. Biol. 2003, 325:979-989.
24. Lee N.K., Kapanidis A.N., Wang Y., Michalet X., Mukhopadhyay J., Ebright R.H., Weiss S. Accurate FRET measurements within single diffusing biomolecules using alternating-laser excitation. Biophys. J. 2005, 88:2939-2953.
25. Marsh J.A., Teichmann S.A. Protein flexibility facilitates quaternary structure assembly and evolution. PLoS Biol. 2014, 12:e1001870.
26. Mimura Y., Church S., Ghirlando R., Ashton P.R., Dong S., Goodall M., Lund J., Jefferis R. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol. Immunol. 2000, 37:697-706.
27. Mimura Y., Sondermann P., Ghirlando R., Lund J., Young S.P., Goodall M., Jefferis R. Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding. J. Biol. Chem. 2001, 276:45539-45547.
28. Pincetic A., Bournazos S., DiLillo D.J., Maamary J., Wang T.T., Dahan R., Fiebiger B.M., Ravetch J.V. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat. Immunol. 2014, 15:707-716.
29. Radaev S., Motyka S., Fridman W.H., Sautes-Fridman C., Sun P.D. The structure of a human type III Fcgamma receptor in complex with Fc. J. Biol. Chem. 2001, 276:16469-16477.
30. Ramsland P.A., Farrugia W., Bradford T.M., Sardjono C.T., Esparon S., Trist H.M., Powell M.S., Tan P.S., Cendron A.C., Wines B.D., Scott A.M., Hogarth P.M. Structural basis for Fc gammaRIIa recognition of human IgG and formation of inflammatory signaling complexes. J. Immunol. 2011, 187:3208-3217.
31. Sazinsky S.L., Ott R.G., Silver N.W., Tidor B., Ravetch J.V., Wittrup K.D. Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:20167-20172.
32. Schierle C.F., Berkmen M., Huber D., Kumamoto C., Boyd D., Beckwith J. The DsbA signal sequence directs efficient, cotranslational export of passenger proteins to the Escherichia coli periplasm via the signal recognition particle pathway. J. Bacteriol. 2003, 185:5706-5713.
33. Schwab I., Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system?. Nat. Rev. Immunol. 2013, 13:176-189.
34. Simmons L.C., Reilly D., Klimowski L., Raju T.S., Meng G., Sims P., Hong K., Shields R.L., Damico L.A., Rancatore P., Yansura D.G. Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J. Immunol. Methods 2002, 263:133-147.
35. Sondermann P., Huber R., Oosthuizen V., Jacob U. The 3.2-Å crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 2000, 406:267-273.
36. Stryer L. Fluorescence energy transfer as a spectroscopic ruler. Annu. Rev. Biochem. 1978, 47:819-846.
37. Tarentino A.L., Gomez C.M., Plummer T.H. Deglycosylation of asparagine-linked glycans by peptide:N-glycosidase F. Biochemistry 1985, 24:4665-4671.
38. Tokuriki N., Tawfik D.S. Protein dynamism and evolvability. Science 2009, 324:203-207.
39. Walsh G. Biopharmaceutical benchmarks 2014. Nat. Biotechnol. 2014, 32:992-1000.
40. Wang X., Kumar S., Buck P.M., Singh S.K. Impact of deglycosylation and thermal stress on conformational stability of a full length murine IgG2a monoclonal antibody: observations from molecular dynamics simulations. Proteins 2013, 81:443-460.
41. Zheng K., Bantog C., Bayer R. The impact of glycosylation on monoclonal antibody conformation and stability. MAbs 2011, 3:568-576.